Immutep (ASX:IMM) has announced positive initial efficacy data and continued favourable safety data from the placebo-controlled, double-blind first-in-human Phase 1 study evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. …
Latest Video
New Stories
-
South Australia expands flu vax availability in response to record outbreak
July 8, 2025 - - Latest News -
MedAdvisor restates focus on US following completion of ANZ business sale
July 8, 2025 - - Latest News -
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 - - Latest News -
Neurotech’s Rett Syndrome trial results published in scientific journal
July 7, 2025 - - Australian Biotech -
PYC Therapeutics to progress polycystic kidney disease trial
July 7, 2025 - - Australian Biotech -
Pharmac minister prepares to deliver letter of expectations
July 7, 2025 - - Latest News -
UK's ten-year plan backs faster access, but industry laments lack of investment
July 7, 2025 - - Latest News